Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Tourmaline Oil Corp. Stock Falls Monday, Underperforms Market

Tourmaline Oil Corp. Stock Falls Monday, Underperforms Market

Dow JonesDow Jones2026/08/24 20:36

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Tourmaline Oil Corp. TOU dropped 0.19% to C$62.16 Monday, in what proved to be an otherwise all-around favorable trading session for the Canadian market, with the S&P/TSX Composite Index rising 0.26% to 36,714.12.

Tourmaline Oil Corp. closed 11.9% below its 52-week high of C$70.57, which the company reached on March 24th.

Trading volume of 1.5 M shares remained below its 50-day average volume of 2.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled August 24, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

August 24, 2026 16:36 ET (20:36 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.

U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).

智通财经2026/09/21 07:11

Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential

According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.

智通财经2026/09/21 07:11

Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.

TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).

智通财经2026/09/21 07:11